Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spermatogenesis-associated protein 5 (SPATA5)
- Target
- SPATA5
- Molecular classification
- Enzyme, AAA+ ATPase (ATPases associated with diverse cellular activities superfamily), Chaperone (ATP-dependent protein chaperone)
01
Overview
Spermatogenesis-associated protein 5 (SPATA5) is an ATP-dependent chaperone in the AAA+ ATPase superfamily. It promotes protein degradation, DNA replication, and chromatin and ribosome remodeling. SPATA5 plays critical roles in mitochondrial integrity during spermatogenesis and cytosolic maturation steps for pre-60S ribosomal particles. Its ATPase activity is stimulated by replication fork DNA and supports replisome proteostasis and chromosome stability during cell division. Pathogenic variants are associated with neurodevelopmental disorders, including epilepsy, hearing loss, and brain structural anomalies. The protein's broad involvement in essential cellular processes links it to chromatin, ribosomal assembly, and membrane fusion, but there are currently no approved drugs or validated clinical biomarkers for this target.
- Other names
- AFG2 AAA ATPase homolog AATPase family gene 2 protein homolog ARibosome biogenesis protein SPATA5Spermatogenesis-associated factor proteinATPase family gene 2 homolog (S. cerevisiae)SPAFAFG2AEHLMRSNEDHSB
02
Mechanism of action
Not well established for therapeutics: Hypothetically: ATPase inhibition (would interfere with protein remodeling/degradation); Chaperone or protease modulation (by altering replisome or ribosome function)
03
Biological functions
Protein degradationDNA replicationMembrane fusionChromatin remodeling and replisome proteostasisRibosome biogenesis (pre-60S ribosomal particle maturation)Mitochondrial maintenance (especially during spermatogenesis)Sister chromatid cohesion and chromosome stability
04
Disease associations
Neurodevelopmental disorders (with hearing loss, seizures, and brain abnormalities)EpilepsyCognitive disability syndromesPeriventricular heterotopia with microcephaly
05
Safety considerations
Potential for off-target effects in any therapy targeting AAA+ ATPases, given essential cellular roles in genome stability, DNA replication, and protein homeostasisLoss-of-function can cause multisystemic developmental disorders, underscoring the risk of interfering with normal protein function
06
Biomarkers
No common clinical biomarkers for patient selection or monitoring have been described for SPATA5/AFG2AVariants may be detected in genetic panels for neurodevelopmental syndromes
Beyond the preview
Go deeper on Spermatogenesis-associated protein 5 (SPATA5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spermatogenesis-associated protein 5 (SPATA5).